Wells Fargo & Company MN lifted its stake in Aduro Biotech, Inc. (NASDAQ:ADRO) by 43.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,439 shares of the biotechnology company’s stock after acquiring an additional 10,376 shares during the period. Wells Fargo & Company MN’s holdings in Aduro Biotech were worth $392,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in Aduro Biotech by 283.7% during the second quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock worth $4,244,000 after buying an additional 275,295 shares in the last quarter. Swiss National Bank boosted its stake in Aduro Biotech by 30.6% during the second quarter. Swiss National Bank now owns 50,300 shares of the biotechnology company’s stock worth $573,000 after buying an additional 11,800 shares in the last quarter. Blair William & Co. IL boosted its stake in Aduro Biotech by 12.5% during the second quarter. Blair William & Co. IL now owns 213,595 shares of the biotechnology company’s stock worth $2,435,000 after buying an additional 23,805 shares in the last quarter. Legal & General Group Plc boosted its stake in Aduro Biotech by 11.2% during the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after buying an additional 1,043 shares in the last quarter. Finally, Alps Advisors Inc. boosted its stake in Aduro Biotech by 9.2% during the second quarter. Alps Advisors Inc. now owns 63,106 shares of the biotechnology company’s stock worth $719,000 after buying an additional 5,310 shares in the last quarter. Institutional investors and hedge funds own 33.63% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was posted by Markets Daily and is the property of of Markets Daily. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.themarketsdaily.com/2017/11/16/aduro-biotech-inc-adro-shares-bought-by-wells-fargo-company-mn.html.
In other Aduro Biotech news, CEO Stephen T. Isaacs sold 40,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $10.78, for a total transaction of $431,200.00. Following the completion of the sale, the chief executive officer now directly owns 213,921 shares of the company’s stock, valued at approximately $2,306,068.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Dirk G. Brockstedt sold 5,877 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $8.00, for a total value of $47,016.00. Following the sale, the executive vice president now directly owns 75,533 shares of the company’s stock, valued at $604,264. The disclosure for this sale can be found here. Insiders sold 217,637 shares of company stock valued at $2,132,780 over the last ninety days. 6.60% of the stock is currently owned by company insiders.
Aduro Biotech, Inc. (NASDAQ ADRO) opened at $8.70 on Thursday. Aduro Biotech, Inc. has a twelve month low of $6.01 and a twelve month high of $14.85.
Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.03). Aduro Biotech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The business had revenue of $3.79 million during the quarter, compared to the consensus estimate of $4.04 million. During the same period in the prior year, the firm earned ($0.54) earnings per share. The business’s quarterly revenue was up .0% compared to the same quarter last year. equities analysts forecast that Aduro Biotech, Inc. will post -1.28 EPS for the current year.
Aduro Biotech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Want to see what other hedge funds are holding ADRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aduro Biotech, Inc. (NASDAQ:ADRO).
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.